(KTTA) Pasithea Therapeutics Corp. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(KTTA) Pasithea Therapeutics Corp. Complete Analysis Pack
Pasithea Therapeutics Business Model Canvas: Biotech Growth, Partnerships, and Risk
Unlock the full Business Model Canvas for Pasithea Therapeutics Corp. to see how the company creates value in biotech, builds partnerships, and positions itself for growth. This concise, professionally written snapshot helps you understand its key activities, revenue logic, and strategic risks. Ideal for investors, analysts, and founders—get the full version for deeper insight.
Partnerships
Contract research organizations
Pasithea Therapeutics Corp. can use CROs to run preclinical studies and clinical trials, including protocol management, site monitoring, and data capture. For a 2020 platform focused on psychiatric and neurological programs, this keeps development lean and lets the company move faster without building every trial function in-house.
Academic and clinical investigators
Academic and clinical investigators in psychiatry and neurology help Pasithea Therapeutics Corp. validate drug candidates, recruit patients, and publish trial data that builds trust. For a development-stage company with a market cap still under $100 million in recent 2025 trading, these partners add scientific credibility and speed up clinical progress.
Ketamine supply and pharmacy partners
Pasithea Therapeutics Corp. depends on reliable ketamine supply and pharmacy partners to keep IV infusion clinics running, because ketamine is a Schedule III controlled substance in the U.S. Pharmacy partners help with 2025-style workflow needs such as preparation, dispensing, and inventory control, which lowers handling errors and supports compliant dosing.
Referral physicians and mental health providers
Referral physicians and mental health providers feed Pasithea Therapeutics Corp.’s depression pipeline with steady patient flow. In the U.S., about 21 million adults had at least one major depressive episode in 2024, and 27% of those cases were treatment-resistant, so community psychiatrists and primary care physicians are key for finding hard-to-treat patients and filling clinic capacity.
- Drive patient referrals
- Lower acquisition cost
- Spot treatment-resistant cases
Real estate and clinic service vendors
Pasithea Therapeutics Corp. depends on real estate and clinic service vendors to open and run new sites, especially in Miami Beach, where leased space, build-outs, medical equipment, and local compliance support must line up before launch.
These partners cut opening delays and keep clinic quality steady, so each expansion can move from lease signing to patient-ready faster.
- Leased space enables clinic expansion
- Construction vendors handle build-outs
- Equipment vendors supply clinic tools
- Compliance vendors support approvals
Pasithea’s Growth Engine: Partners Power Trials, Supply, and Patient Flow
Key partnerships for Pasithea Therapeutics Corp. center on CROs, academic investigators, pharmacies, referral clinicians, and clinic vendors. These partners help run trials, validate data, keep ketamine supply compliant, and feed patient flow into a U.S. depression market where 21 million adults had a major depressive episode in 2024 and 27% were treatment-resistant.
| Partner | Role | Value |
|---|---|---|
| CROs | Run trials | Speed |
| Pharmacies | Supply ketamine | Compliance |
| Referrals | Send patients | Lower CAC |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Pasithea Therapeutics Corp. aligned to its therapeutic development strategy and stakeholder needs.
Customizable Excel Spreadsheet
Quickly maps Pasithea Therapeutics Corp.’s Business Model Canvas to spot pain points and streamline strategy review.
Reference Sources
Pasithea Therapeutics Corp. Reference Sources provide a clear, traceable basis for key claims, boosting credibility and supporting faster, better decisions.
Activities
Therapeutic discovery
Pasithea Therapeutics Corp. uses therapeutic discovery to find novel treatments for 2 core areas: psychiatric and neurological conditions. This biotech work centers on target assessment and candidate selection, and as of FY2025 the Company remained preclinical with no approved therapies, so discovery is the main value driver.
Clinical development
Pasithea Therapeutics Corp. centers its clinical development on advancing drug candidates like PAS-004 through Phase 1/1b testing, with study design, patient enrollment, and safety review guiding each step. These trials are the gate before commercialization, since human safety and dose data must be built before any launch decision.
Depression clinic operations
Pasithea Therapeutics Corp. plans depression clinics that handle scheduling, screening, treatment delivery, and follow-up, adding a recurring service line beyond R&D. That matters in a large care gap: the U.S. had about 23% of adults, or 59.3 million people, with any mental illness in 2022, supporting steady clinic demand.
Intravenous ketamine administration
Trained pharmacists administer Pasithea Therapeutics Corp.’s IV ketamine infusions with tight dose control and monitored care, since a standard session lasts about 40 minutes and is followed by at least 1-2 hours of observation for blood pressure, dissociation, and sedation. The service is built for rapid-acting depression treatment, where symptom relief can begin within hours.
- Pharmacist-led infusion delivery
- Controlled dosing and monitoring
- Medical oversight for safety
- Targets fast depression relief
Regulatory and quality compliance
Regulatory and quality compliance is core for Pasithea Therapeutics Corp.: biotech and clinic work must run through IRB review, tight documentation, and prompt safety reporting under rules like 21 CFR Part 11 and 45 CFR 46. One missed report can halt a study, so clean records protect both care and research.
- IRB approval before enrollment
- Audit-ready source docs
- Fast SAE reporting
Pasithea Focused on Early Trials and Clinic Growth in FY2025
Pasithea Therapeutics Corp.'s key activities are preclinical drug discovery, Phase 1/1b testing of PAS-004, and building pharmacist-led ketamine clinics. In FY2025, the Company stayed pre-approval, so target validation, trial execution, and safety oversight remained the core work.
| Activity | FY2025 focus | Why it matters |
|---|---|---|
| R&D and clinics | Preclinical plus early trials | Drives future revenue |
Full Version Awaits
Business Model Canvas
This Pasithea Therapeutics Corp. Business Model Canvas preview is the exact same document you’ll receive after purchase, not a mockup or placeholder. What you see here is a direct snapshot of the final file, formatted and structured exactly as delivered. Once your order is complete, you’ll get full access to this same ready-to-use document.
Resources
Scientific pipeline
Pasithea Therapeutics Corp.'s scientific pipeline is its main value-creation asset, with therapeutic programs focused on psychiatric and neurological disorders. That pipeline is the base for long-term growth, because each successful program can add clinical, regulatory, and commercial value.
Clinical care protocols
Clinical care protocols are a key resource for Pasithea Therapeutics Corp. because they standardize ketamine screening, dosing, and post-dose monitoring, which is critical for safe clinic operations. FDA-approved esketamine treatment requires at least 2 hours of supervised observation after each dose, and that same discipline helps reduce avoidable adverse events while keeping care consistent.
Specialized staff
Pasithea Therapeutics Corp. is still clinical-stage in 2025, so its key resource is human capital: trained pharmacists, scientists, and clinical staff who run drug development and clinic services. That expertise matters more than physical assets because it supports trial design, patient care, and regulatory work at the same time.
Miami Beach headquarters
Pasithea Therapeutics Corp. is based in Miami Beach, Florida, and its headquarters anchor administration, strategy, and coordination across research and clinic activities. For a small biotech, a central office keeps decision-making tight and helps align lab work, patient-facing ops, and corporate control.
- Miami Beach HQ
- Runs admin and strategy
- Coordinates research and clinics
Capital and investor access
Capital and investor access is a core resource for Pasithea Therapeutics Corp because biotech trials and clinic expansion need constant cash. As a 2020 public company, access to equity markets helps fund R&D, hire staff, and build out sites without pausing the pipeline.
- Funds trials and clinic buildout
- Supports hiring and operating costs
- Public listing widens financing access
Pasithea’s 2025 edge: pipeline, expertise, and funding access
Pasithea Therapeutics Corp.’s key resources are its clinical pipeline, ketamine care protocols, and specialized staff. In 2025, the company stayed clinical-stage, so scientific know-how and regulatory execution matter more than physical assets. Its Miami Beach HQ and public listing also support coordination and funding.
| Resource | 2025 detail |
|---|---|
| Pipeline | Psychiatric and neurological programs |
| Staff | Trained scientists and clinic teams |
| Capital access | Public-company financing |
Value Propositions
Novel psychiatric and neurological therapies
Pasithea Therapeutics Corp. targets unmet mental health and neurological needs with novel therapies, aiming to create new options where current choices are still limited. The addressable need is large: the WHO says 1 in 8 people live with a mental disorder, and almost 1 billion people have a neurological condition, so future innovation can matter fast.
Rapid depression treatment access
IV ketamine clinics give Pasithea Therapeutics Corp. a fast-response edge: studies show symptom relief can begin within 24 hours, while standard antidepressants often take 2-6 weeks. In treatment-resistant depression, short-term response rates in published trials have often been about 50%-70%, making speed a clear clinical differentiator.
Integrated biotech plus clinic model
Pasithea Therapeutics Corp. pairs biotech research with clinic-based care, so discovery can feed directly into treatment use and back again. That real-world loop gives the model more than a pure lab setup and can sharpen how the company tests, learns, and adapts across patient care.
Specialized supervised infusion care
Pasithea Therapeutics Corp. value is in supervised IV ketamine care: trained pharmacists add procedural control, which can support consistent dosing and a better patient experience in depression clinics. This matters in a large market, with about 21.5 million U.S. adults reporting at least one major depressive episode in 2023.
- Pharmacist-led IV administration
- Better dosing consistency
- Clinic fit for depression care
Access to emerging care pathways
Patients and providers get access to newer psychiatry pathways, especially where standard therapies have failed; about 30% of major depressive disorder patients are treatment-resistant, so the clinical need is real. For Pasithea Therapeutics Corp., this value proposition links innovation to unmet demand, not just product novelty.
- Targets treatment-resistant patients
- Supports provider option-set expansion
- Matches high unmet psychiatric need
That focus can matter most when first-line care has low response and patients need faster, different approaches.
Ketamine Care Targets Fast Relief in Depression
Pasithea Therapeutics Corp. offers supervised IV ketamine care and a biotech pipeline aimed at faster relief in hard-to-treat depression, where speed and access still matter. In 2025, the U.S. FDA kept ketamine-based care in focus as depression treatment demand stayed high, with 2023 CDC data showing 21.5 million U.S. adults had at least one major depressive episode.
| Value driver | Data point |
|---|---|
| Depression need | 21.5M U.S. adults |
| Fast response | ~24 hours for ketamine |
| Unmet need | ~30% TRD rate |
Customer Relationships
Provider-supervised treatment
Pasithea Therapeutics Corp. uses provider-supervised treatment so clinic patients receive care under trained clinical oversight, which matters in a high-acuity setting where trust is built through visible monitoring. This model also supports safe observation during IV infusion sessions, helping staff watch for rapid changes and respond fast when needed.
High-touch onboarding
Pasithea Therapeutics Corp.’s high-touch onboarding fits its Phase 1/2 development model: patients usually need screening, intake, eligibility review, and treatment education before dosing. That keeps expectations clear and helps lower clinical risk when every enrolled patient matters.
Referral-based engagement
Pasithea Therapeutics Corp. can rely on physician and mental health referrals to fill demand, which cuts patient acquisition friction and sends higher-fit patients into care. This matters because referral-driven channels typically move patients faster than paid marketing, and they help Pasithea Therapeutics Corp. focus on clinically appropriate cases.
Follow-up and maintenance contact
Pasithea Therapeutics Corp. can use follow-up and maintenance contact to track response after the first depression visit, since symptoms often need repeat assessment and treatment changes. This keeps patients engaged, supports continued service use, and improves retention; in practice, early follow-up is tied to lower drop-off in ongoing care.
- Repeat checks track mood and side effects
- Ongoing contact supports adherence
- Regular touchpoints help retain patients
Investor and scientific communication
Pasithea Therapeutics Corp. relies on clear investor and scientific communication because trial milestones and clinic rollout updates directly affect market trust in a public company. For a biotech, steady disclosure on clinical progress, patient activity, and site development helps reduce uncertainty and keep shareholders aligned.
- Trial updates support confidence
- Clinic progress signals execution
- Public disclosure shapes valuation
Physician-Led Trust Drives Pasithea’s Patient Retention
Pasithea Therapeutics Corp. builds customer ties through physician-led intake, supervised dosing, and repeated follow-up, so trust comes from visible clinical oversight, not mass marketing. In 2025, this fit a small, high-acuity patient base where every referral and retained visit matters more than volume.
Ongoing symptom checks and side-effect reviews keep patients engaged and support adherence during repeat treatment.
| Channel | Role |
|---|---|
| Referrals | High-fit patient flow |
| Clinic visits | Trust and monitoring |
| Follow-up | Retention and adherence |
Channels
Direct clinic locations
Pasithea-operated clinics are the main access point for care, and they are the physical sites used for IV ketamine delivery. A typical ketamine induction course is 6–8 infusions over 2–4 weeks, so this channel keeps treatment tightly controlled and in person.
Physician referrals
Physician referrals are a high-trust channel for Pasithea Therapeutics Corp., because psychiatrists and other clinicians can send treatment-resistant depression patients directly into care. That matters in a market where roughly 30% of major depressive disorder cases are treatment-resistant, so referrals can improve patient flow, lower acquisition friction, and strengthen clinical credibility.
Company website and digital outreach
Pasithea Therapeutics Corp uses its company website and digital outreach to explain treatment options, eligibility, and next steps, so patients and caregivers can move from search to contact quickly. For a health platform, that online presence matters because clinic discovery and appointment access happen first on mobile and web, not in person.
Clinical trial recruitment
Pasithea Therapeutics Corp. uses clinical trial recruitment to fill research programs with eligible patients, mainly through investigators, patient databases, and specialty communities. In a market where ClinicalTrials.gov listed 500,000+ studies in 2026, fast outreach matters because it keeps drug development moving and helps preserve trial timelines.
- Investigators drive site-level referrals
- Databases speed patient matching
- Specialty groups widen rare-disease reach
Investor and media communications
Pasithea Therapeutics Corp. uses public-company disclosures, including SEC filings and press releases, to show trial progress, cash needs, and strategic updates to the market. This channel also lifts brand awareness because every filing and release reaches investors, analysts, and media, which matters when a small-cap biotech needs both financing and visibility.
- SEC filings support transparency.
- Press releases expand market reach.
- Visibility helps fundraising access.
How Pasithea Fills Clinics, Referrals, and Trials
Pasithea Therapeutics Corp. relies on clinic sites, physician referrals, web outreach, and trial recruitment to move patients into care and studies. Its channel mix is built for high-touch treatment: ketamine induction usually needs 6–8 infusions over 2–4 weeks, while referral-led access can speed entry for the about 30% of major depressive disorder cases that are treatment-resistant.
| Channel | Use | Key data |
|---|---|---|
| Clinics | IV ketamine delivery | 6–8 infusions |
| Referrals | Patient intake | ~30% TRD rate |
| ClinicalTrials.gov | Trial recruitment | 500,000+ studies |
Customer Segments
Adults with treatment-resistant depression
Adults with treatment-resistant depression are a core clinic segment for Pasithea Therapeutics Corp., because they may seek rapid-acting options after at least 2 failed antidepressant trials. About 30% of people with major depressive disorder do not respond adequately to standard care, which supports demand for ketamine-based treatment models.
Patients with psychiatric disorders
Pasithea Therapeutics Corp targets patients with psychiatric disorders, including depression and related mental health needs, a group that spans millions of people; for context, the WHO estimates about 280 million people live with depression worldwide. This fits its therapeutic focus on broader psychiatric care, where demand stays high and treatment gaps remain wide.
Neurology trial participants
Neurology trial participants are patients with CNS diseases who enroll in Pasithea Therapeutics Corp.’s clinical studies, usually in small phase 1/2 cohorts. Their data help test novel candidates, guide dose and safety readouts, and feed the biotech pipeline that drives future value.
Referring clinicians
Referring clinicians, especially psychiatrists and primary care physicians, are key gatekeepers for Pasithea Therapeutics Corp. They are not always the end users, but their referrals can decide who enters care and how full clinics run; in U.S. mental health care, primary care handles a large share of first contact, so a strong referral flow can directly lift utilization.
- Psychiatrists drive specialty referrals.
- Primary care physicians shape first access.
- Referrals can raise clinic volume fast.
Health-conscious self-pay patients
Health-conscious self-pay patients often pay directly for specialized depression care when they want faster access, privacy, or treatments not covered by insurance. In specialty mental health, cash-pay visits often run about $100-$300 per session, so this segment can add high-margin clinic revenue and support demand for emerging care models.
- Direct pay lowers payer friction.
- Specialty care can command premium pricing.
- Fast access helps convert motivated patients.
Pasithea Targets TRD Adults, Referrals, and Premium Cash Patients
Pasithea Therapeutics Corp. serves adults with treatment-resistant depression, a group that still makes up about 30% of major depressive disorder patients. It also reaches psychiatrists, primary care doctors, and self-pay patients who want faster, specialist-led care, plus trial participants who support CNS drug studies.
| Segment | Why it matters |
|---|---|
| TRD adults | Core clinic demand |
| Referring doctors | Feed patient flow |
| Self-pay patients | Support premium cash revenue |
Cost Structure
Research and development spending
In fiscal 2025, Pasithea Therapeutics Corp. remained a research-heavy biotech, where drug discovery and preclinical work burn cash fast through assays, experiments, and scientific labor. This cost line is usually the biggest operating expense for early-stage biotech, because each test and study adds direct lab spend and staff cost.
Clinical trial costs
Human studies are one of Pasithea Therapeutics Corp.’s biggest cost drivers because they need trial sites, monitors, data systems, and safety review. In 2025, multicenter Phase 2 programs often ran into the low millions of dollars, and costs usually jump again as trials add more patients and longer follow-up.
Clinic buildout and staffing
Pasithea Therapeutics Corp. must lease space, fit out treatment rooms, and buy equipment before a clinic can open, so each new site adds upfront cash needs. Staffing then adds fixed payroll for pharmacists and support personnel, and that cost base does not scale down easily; in FY2025, clinic expansion should therefore pressure SG&A before patient volume catches up.
Regulatory and compliance expense
Regulatory and compliance expense for Pasithea Therapeutics Corp. covers SEC filings, legal review, and safety documentation, and it rises with public-company reporting. In regulated biotech, this is a fixed must-have, because every trial update and disclosure needs review before release.
- SEC reporting adds overhead
- Safety docs need constant updates
- Legal review slows every filing
For Pasithea Therapeutics Corp., these costs are part of staying audit-ready and trial-compliant, not optional spend.
General and administrative overhead
General and administrative overhead covers corporate administration, finance, and management, plus Miami Beach headquarters support, so it stays on the books even before product sales grow.
- Fixed HQ costs
- Admin and finance staff
- Pre-revenue burden
Pasithea’s FY2025 Costs Stayed Heavy on R&D, Trials, and Overhead
In fiscal 2025, Pasithea Therapeutics Corp.'s cost structure stayed dominated by R&D, clinical trial spend, and fixed public-company overhead. Phase 2 studies can run in the low millions, and each new clinic adds lease, fit-out, staffing, and compliance costs before revenue can catch up.
| Cost line | FY2025 pressure |
|---|---|
| R&D | Highest cash burn |
| Trials | Low millions per Phase 2 |
| G&A | Fixed HQ overhead |
Revenue Streams
IV ketamine treatment fees
IV ketamine treatment fees are the clearest near-term service revenue stream for Pasithea Therapeutics Corp., with patients paying for each infusion plus medical supervision. In the U.S., ketamine infusion sessions often cost about $400 to $800 each, so even modest volume can create recurring clinic cash flow.
Consultation and follow-up fees
Pasithea Therapeutics Corp. can bill initial assessments and follow-up visits separately, so one care episode can turn into 4 billable touchpoints if a patient has 1 intake visit and 3 monitoring visits. This stream supports treatment planning and tracking, and it lifts revenue per patient by spreading fees across each step of care.
Clinical trial service revenue
Clinical trial service revenue can come from sponsor-paid execution, monitoring, and data work, which is a standard early-stage biotech income line. For Pasithea Therapeutics Corp., this stream is still limited and typically sits beside capital raises, so even modest contracted study work can matter more than the absolute revenue size.
Licensing and milestone income
Pasithea Therapeutics Corp. can turn a successful candidate into a licensing deal, then add milestone income when development or commercialization targets are hit. This is a classic biotech upside stream: upfront cash can be modest, but single licensing deals in 2024 often reached tens of millions of dollars plus future milestones.
- License IP after candidate progress
- Earn development milestone payments
- Capture commercialization upside
Grant and collaboration funding
Grant and collaboration funding can bring non-dilutive cash to Pasithea Therapeutics Corp., so research programs can advance without issuing more shares. Partnership payments and institutional support can help offset R&D spend and reduce pressure on the balance sheet.
- Non-dilutive cash supports research.
- Partner funding can cover R&D costs.
- Helps reduce equity dilution risk.
Pasithea’s Near-Term Cash Engine: Paid Ketamine Sessions
Pasithea Therapeutics Corp. earns near-term cash from paid ketamine infusions, with U.S. sessions often priced at $400-$800, plus separate intake and follow-up fees that can lift revenue per patient.
| Stream | 2025/2026 cue |
|---|---|
| Ketamine care | $400-$800/session |
| Trials | Sponsor-paid services |
| Licensing | Milestones + royalties |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.